JP5596861B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP5596861B2 JP5596861B2 JP2013523129A JP2013523129A JP5596861B2 JP 5596861 B2 JP5596861 B2 JP 5596861B2 JP 2013523129 A JP2013523129 A JP 2013523129A JP 2013523129 A JP2013523129 A JP 2013523129A JP 5596861 B2 JP5596861 B2 JP 5596861B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- calculated
- cap
- hcv
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *CI(*)I(C=C1)=Cc2c1[n]c(C1N(*)CCC1)n2 Chemical compound *CI(*)I(C=C1)=Cc2c1[n]c(C1N(*)CCC1)n2 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- XNWKQVYSSMQUAR-GJZGRUSLSA-N Bc1cc2ccc3nc([C@H](CC4)N[C@H]4N4CC4)[nH]c3c2cc1 Chemical compound Bc1cc2ccc3nc([C@H](CC4)N[C@H]4N4CC4)[nH]c3c2cc1 XNWKQVYSSMQUAR-GJZGRUSLSA-N 0.000 description 1
- KSVFZBFIDPVZMG-RKCPAPCSSA-N C1C2(c3nc(-c(c(CCC4)c5)ccc5-c(cc5)cc6c5nc([C@H]5NCCC5)[nH]6)c4[nH]3)NCC[C@@H]12 Chemical compound C1C2(c3nc(-c(c(CCC4)c5)ccc5-c(cc5)cc6c5nc([C@H]5NCCC5)[nH]6)c4[nH]3)NCC[C@@H]12 KSVFZBFIDPVZMG-RKCPAPCSSA-N 0.000 description 1
- KSVFZBFIDPVZMG-ZZLYJBIYSA-N C1[C@@]2(c3nc(-c(c(CCC4)c5)ccc5-c(cc5)cc6c5nc([C@H]5NCCC5)[nH]6)c4[nH]3)NCC[C@@H]12 Chemical compound C1[C@@]2(c3nc(-c(c(CCC4)c5)ccc5-c(cc5)cc6c5nc([C@H]5NCCC5)[nH]6)c4[nH]3)NCC[C@@H]12 KSVFZBFIDPVZMG-ZZLYJBIYSA-N 0.000 description 1
- JVWZSHDIPVXYQE-UHFFFAOYSA-N CC(C(O)=O)(c1ccccc1)N(C)C Chemical compound CC(C(O)=O)(c1ccccc1)N(C)C JVWZSHDIPVXYQE-UHFFFAOYSA-N 0.000 description 1
- SVMADPCXAYAMEH-FQEVSTJZSA-N CC(C)(C)OC(N(CCCC1)[C@@H]1c1ncc(-c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)[nH]1)=O Chemical compound CC(C)(C)OC(N(CCCC1)[C@@H]1c1ncc(-c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)[nH]1)=O SVMADPCXAYAMEH-FQEVSTJZSA-N 0.000 description 1
- KNBUOUMLKOVMSP-RUDMXATFSA-N CC(C)C(/C=N/C(OC)=O)C(O)=O Chemical compound CC(C)C(/C=N/C(OC)=O)C(O)=O KNBUOUMLKOVMSP-RUDMXATFSA-N 0.000 description 1
- ICQSBMUCISIMPR-VUOSCZECSA-N CC(C)CN(Cc1nc(ccc(C#Cc2cc3ccc4nc([C@H](C[C@H](C)C5)N5C(C(C5)(C(C)C)[C@@H]5NC(OC)=O)=O)[nH]c4c3cc2)c2)c2[nH]1)C([C@H](C(C)C)NC(OC)=O)=O Chemical compound CC(C)CN(Cc1nc(ccc(C#Cc2cc3ccc4nc([C@H](C[C@H](C)C5)N5C(C(C5)(C(C)C)[C@@H]5NC(OC)=O)=O)[nH]c4c3cc2)c2)c2[nH]1)C([C@H](C(C)C)NC(OC)=O)=O ICQSBMUCISIMPR-VUOSCZECSA-N 0.000 description 1
- AJSWQDZQEHSVQC-CUPIEXAXSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(c(CCC2)c3)ccc3-c(cc3)cc4c3nc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]4)c2[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(c(CCC2)c3)ccc3-c(cc3)cc4c3nc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]4)c2[nH]1)=O)NC(OC)=O AJSWQDZQEHSVQC-CUPIEXAXSA-N 0.000 description 1
- CIHYNURPOFWVHE-UHFFFAOYSA-N CC(C1)(C1NC(N(C)C)=O)C(O)=O Chemical compound CC(C1)(C1NC(N(C)C)=O)C(O)=O CIHYNURPOFWVHE-UHFFFAOYSA-N 0.000 description 1
- WFNCZUIGZZVNKH-UHFFFAOYSA-N CCc1cccnc1C(OC)=O Chemical compound CCc1cccnc1C(OC)=O WFNCZUIGZZVNKH-UHFFFAOYSA-N 0.000 description 1
- CWLQUGTUXBXTLF-RXMQYKEDSA-N CN(CCC1)[C@H]1C(O)=O Chemical compound CN(CCC1)[C@H]1C(O)=O CWLQUGTUXBXTLF-RXMQYKEDSA-N 0.000 description 1
- FCCGCNDUVPFVKZ-OXJNMPFZSA-N C[C@@H](c1ccccc1)OC([C@@H](c(cccc1)c1F)N1CCCCC1)=O Chemical compound C[C@@H](c1ccccc1)OC([C@@H](c(cccc1)c1F)N1CCCCC1)=O FCCGCNDUVPFVKZ-OXJNMPFZSA-N 0.000 description 1
- RPTRFSADOICSSK-UHFFFAOYSA-N OC(Cc1ccccc1F)=O Chemical compound OC(Cc1ccccc1F)=O RPTRFSADOICSSK-UHFFFAOYSA-N 0.000 description 1
- JWEVOPISFCSQTI-GFCCVEGCSA-N OC([C@@H](c(cccc1)c1F)N1CCCCC1)=O Chemical compound OC([C@@H](c(cccc1)c1F)N1CCCCC1)=O JWEVOPISFCSQTI-GFCCVEGCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/044356 WO2012018325A1 (en) | 2010-08-04 | 2010-08-04 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532725A JP2013532725A (ja) | 2013-08-19 |
| JP2013532725A5 JP2013532725A5 (enExample) | 2013-09-26 |
| JP5596861B2 true JP5596861B2 (ja) | 2014-09-24 |
Family
ID=43640063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523129A Expired - Fee Related JP5596861B2 (ja) | 2010-08-04 | 2010-08-04 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2601188B1 (enExample) |
| JP (1) | JP5596861B2 (enExample) |
| KR (1) | KR20140045903A (enExample) |
| CN (1) | CN103153986B (enExample) |
| AU (1) | AU2010358561B2 (enExample) |
| BR (1) | BR112013002729A2 (enExample) |
| CA (1) | CA2807305A1 (enExample) |
| EA (1) | EA022127B1 (enExample) |
| IL (1) | IL224298A (enExample) |
| MX (1) | MX337936B (enExample) |
| SG (1) | SG187183A1 (enExample) |
| WO (1) | WO2012018325A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8673954B2 (en) * | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8354419B2 (en) | 2009-07-16 | 2013-01-15 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012158861A2 (en) | 2011-05-18 | 2012-11-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9073943B2 (en) | 2012-02-10 | 2015-07-07 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| CA2869908C (en) | 2012-04-25 | 2018-02-20 | Theravance Biopharma R&D Ip, Llc | Hepatitis c virus inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN110621652A (zh) | 2017-05-17 | 2019-12-27 | 株式会社德山 | 二氨基苯化合物的制造方法 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3816151A1 (en) | 2018-06-28 | 2021-05-05 | Tokuyama Corporation | Method for producing ?-azidoaniline derivative or ?, ?'-diazide derivative |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| KR20050062551A (ko) * | 2002-09-20 | 2005-06-23 | 기린 비루 가부시키가이샤 | α-글리코실세라미드를 유효 성분으로 하는 Ｃ형 간염 바이러스 억제제 |
| GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010065668A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
-
2010
- 2010-08-04 KR KR1020137005316A patent/KR20140045903A/ko not_active Abandoned
- 2010-08-04 MX MX2013001237A patent/MX337936B/es active IP Right Grant
- 2010-08-04 CN CN201080069468.6A patent/CN103153986B/zh not_active Expired - Fee Related
- 2010-08-04 CA CA2807305A patent/CA2807305A1/en not_active Abandoned
- 2010-08-04 SG SG2013005558A patent/SG187183A1/en unknown
- 2010-08-04 AU AU2010358561A patent/AU2010358561B2/en not_active Ceased
- 2010-08-04 WO PCT/US2010/044356 patent/WO2012018325A1/en not_active Ceased
- 2010-08-04 EP EP10740116.8A patent/EP2601188B1/en not_active Not-in-force
- 2010-08-04 EA EA201370017A patent/EA022127B1/ru not_active IP Right Cessation
- 2010-08-04 BR BR112013002729A patent/BR112013002729A2/pt not_active IP Right Cessation
- 2010-08-04 JP JP2013523129A patent/JP5596861B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-17 IL IL224298A patent/IL224298A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2807305A1 (en) | 2012-02-09 |
| JP2013532725A (ja) | 2013-08-19 |
| KR20140045903A (ko) | 2014-04-17 |
| CN103153986B (zh) | 2014-11-05 |
| CN103153986A (zh) | 2013-06-12 |
| EP2601188B1 (en) | 2017-10-18 |
| AU2010358561B2 (en) | 2016-06-02 |
| SG187183A1 (en) | 2013-02-28 |
| MX2013001237A (es) | 2013-05-28 |
| AU2010358561A1 (en) | 2013-03-21 |
| EP2601188A1 (en) | 2013-06-12 |
| IL224298A (en) | 2015-08-31 |
| MX337936B (es) | 2016-03-29 |
| EA201370017A1 (ru) | 2013-05-30 |
| EA022127B1 (ru) | 2015-11-30 |
| BR112013002729A2 (pt) | 2016-05-31 |
| WO2012018325A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5612612B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5558556B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5632910B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| AU2010358561B2 (en) | Hepatitis C virus inhibitors | |
| JP5599792B2 (ja) | Ｃ型肝炎ウイルス阻害剤としてのｂｉ−１ｈ−ベンズアミダゾール | |
| JP5615352B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5455933B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5425815B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| US8394968B2 (en) | Hepatitis C virus inhibitors | |
| JP2011511841A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2010527373A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| HK1163067B (en) | Hepatitis c virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130704 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130704 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140710 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140715 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140807 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5596861 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |